Columbia Threadneedle’s Corporate Income Fund returned 2.05% in Q2 2025 amid market volatility and tariff shocks. Explore how ...

XONE offers low-cost, short-duration Treasury exposure, making it attractive for those seeking limited duration risk. See why ...

Columbia Threadneedle’s Convertible Securities Fund beat its benchmark in Q2 2025, fueled by tech and crypto-linked ...

Suzano maintains a strong cost advantage in pulp production, exporting to stable and growing markets, creating a solid moat ...

The pan-European Stoxx 600 ( STOXX) ticked 0.1% lower on Monday as investors traded with caution ahead of President Trump's meeting with Ukrainian President Volodymyr Zelenskyy and European leaders in ...

The most likely range for 3-month bill yields falls to the 1% to 2% range within 30 months, according to this week’s ...

Columbia Threadneedle’s Contrarian Core Fund beat its benchmark in Q2 2025 amid AI-fueled tech gains. Explore what drove ...

Gilead Sciences' valuation exceeds fundamentals, prompting a SELL recommendation. Discover why this $150B biopharma stock may ...

Rocket Pharmaceuticals is down 85% as key programs face FDA setbacks, despite a cash runway to 2027 and in vivo promise. Read ...

Columbia Threadneedle’s Bond Fund beat its benchmark in Q2 2025 with smart duration and credit picks. See how it navigated ...

Schlumberger is undervalued vs. peers, with ChampionX synergies, solid financials, and segment growth offsetting risks. Find ...

After a strong June, the REIT sector recovery stalled in July as REITs fell to a -6.42% year-to-date return. Read more here.